Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B vaccine (recombinant) (modified process)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Hepatitis B vaccine (recombinant) (modified process) is a non-infectious subunit viral vaccine designed to prevent infection caused by the hepatitis B virus (HBV). It is produced using recombinant DNA technology, where the gene encoding the hepatitis B surface antigen (HBsAg) is inserted into yeast cells, typically *Saccharomyces cerevisiae*. These genetically engineered yeast cells then produce HBsAg, which is harvested and purified. When administered, this HBsAg stimulates the body's immune system to produce specific antibodies against HBV, thereby conferring active immunity and protecting against HBV infection, which can lead to severe liver diseases such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The "modified process" refers to manufacturing advancements aimed at reducing variability and optimizing the immunogenicity of the vaccine.
- Brand names
- Recombivax HBEngerix-BHeplisav-BPreHevbrioHeptavax-IISci-B-Vac
- Other names
- HepB vaccinerecombinant hepatitis B vaccinegenetically engineered vaccine for hepatitis Binactivated (recombinant) vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis B vaccine (recombinant) (modified process).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B vaccine (recombinant) (modified process).